Table 2 Ruxolitinib treatment prior to allograft (n = 277).
Discontinuation of RUX prior to allograft (for reasons other than transplant) (n = 245, 88%) | n = 56 (23%) |
Tapering of RUX prior to discontinuation (n = 245, 88%) | |
Yes | n = 117 (48%) |
No | n = 128 (52%) |
Median starting dose of RUX/day | 30 mg (range: 5–80) |
Median dose at last period/day | 20 mg (range: 5–50) |
Reasons of early discontinuation (n = 56, 100%) | |
No response | n = 16 (29%) |
Loss of response | n = 5 (9%) |
Toxicity | n = 13 (23%) |
Others | n = 22 (39%) |
Rebound phenomenon after stopping RUX (n = 245, 88%) | n = 15 (6%) |
Median spleen size at start of RUX (palpable in cm) (n = 141, 51%) | 12 cm (1–32) |
Constitutional symptoms at start of RUX (n = 219, 79%) | |
Yes | n = 190 (87%) |
No | n = 29 (13%) |
Best response to RUX (n = 227, 82%) | |
Spleen size > 50% | n = 39 (17%) |
Spleen size < 50% | n = 88 (39%) |
No response | n = 100 (44%) |
Response of RUX to spleen size at time of transplant (n = 195, 70%) | |
Spleen response > 50% | n = 25 (13%) |
Spleen response < 50% | n = 66 (34%) |
Lost spleen response | n = 23 (12%) |
No spleen response | n = 81 (42%) |
Median duration of RUX treatment (months) (n = 219, 79%) | 7.6 |
Infections during RUX treatment (n = 277, 100%) | |
Yes | n = 25 (11%) |
No | n = 210 (89%) |
